Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

[Figure: see text].

Saved in:
Bibliographic Details
Published inCirculation. Cardiovascular interventions Vol. 14; no. 4; p. e009434
Main Authors Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean-Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., ten Berg, Jurriën M.
Format Journal Article
LanguageEnglish
Published United States Lippincott Williams & Wilkins 01.04.2021
Subjects
clopidogrel
percutaneous coronary intervention
acute coronary syndrome
genetic testing
myocardial infarction
ticagrelor
pharmacogenetics
Online AccessGet full text

Cover

More Information
Summary:[Figure: see text].
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1941-7632
1941-7640
1941-7632
DOI:10.1161/CIRCINTERVENTIONS.120.009434